期刊文献+

ITOP方案治疗复发或难治性非霍奇金淋巴瘤疗效分析 被引量:3

下载PDF
导出
摘要 目的 探讨ITOP方案治疗复发或难治性非霍奇金淋巴瘤的疗效和毒性。方法 45例患者予ITOP方案治疗:异环磷酰胺1.2g/(m^2·d)静脉滴注,第1~5天:吡柔比星30mg/(m^2·d)静脉注射,第1~3天;长新春碱1.4mg/(m^2·d)静脉注射,第1天;泼尼松40mg/(m^2·d)口服,第1~7天。每3周为1个周期,全组患者接受3~8个周期治疗,平均4个周期。结果 完全缓解23例,部分缓解11例,总有效率为75.56%,平均生存期为(44±28)个月,毒副作用主要为骨髓抑制。结论 ITOP方案是治疗复发或难治性非霍奇金淋巴瘤的有效方案,毒性反应可耐受。
出处 《中国医师进修杂志(内科版)》 2006年第7期45-46,48,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献7

  • 1邓家栋.临床血液病学[M].北京:人民卫生出版社,2001.1317-1323.
  • 2王奇璐.恶性淋巴瘤诊断和治疗[M].北京:北京医科大学、中国协和医科大学联合出版社,1997.226.
  • 3Ezzat AA, Ibrahim EM, Stuart RK, et al. Adding high dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin lymphoma: an interim analysis of a randomized phase Ⅲ tria. Med Oncol ,2000 ,17 (1): 39-46.
  • 4Beiser M, Schnell R, Straub GD. IZE:an effective and well tolerated new regimen for patients with relapsed lymphoma. Leuk Lymph,1998, 34(2): 359-366.
  • 5林菁,张军一,李鸣芳,罗荣城.ICE方案治疗复发性难治性非霍奇金淋巴瘤20例[J].实用医学杂志,2005,21(2):169-170. 被引量:6
  • 6李旭芬,兰琼,黄建瑾.IHOP方案治疗非霍奇金淋巴瘤50例临床疗效评价[J].中国癌症杂志,2004,14(3):291-292. 被引量:11
  • 7Pohlman B. Ifosfamide in the treatment of non - Hodgkin lymphoma.Semin Oncol, 1996 ,23 (Suppl 6):a27-a32.

二级参考文献15

  • 1Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins. N Engl J Med, 1993, 328(14): 1002 - 1006.
  • 2Moskowitz CH, Nimer SD, Glassman JR, et al. The International Prognostic Index predicts for outcome following ASCT in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant, 1999, 23(6): 561 - 567.
  • 3McCoy AG,Smith EP, Atkinson ME, et al. A novel preparative regimen for autologous transplant in non-Hodgkin' s lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant, 2004,33(1): 19 -24.
  • 4Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin,and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-Cell mobilization regimen for transplant-eligible patients with non-Hodgkin' s lymphoma. J Clin Oncol, 1999, 17( 12): 3776 - 3785.
  • 5Sawada M,Tsurumi H,Yamada T,et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy[J]. Eur J Haematol,2002,68(6):
  • 6Shipp MA, Mauch PM, Harris NL. Non-Hodgkin's lymphomas[A]. In: Devita VT Jr, Hellmen S, Rosenberg SA, eds. Cancer, principles and practice of oncology[M].5ed. Philadelphia:New York :Lippincott-Raven. 1997:2165-2220.
  • 7Tirelli U, Errante D, Van GM, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of
  • 8Ezzat AA, Ibrahim EM, Stuart RK, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial[J]. Med Oncol,2000,17(1): 39-46.
  • 9Brade WP, Herdrich K, Varini M, et al. Ifosfamide-pharmacology, safety and theraputic potential[J]. Cancer Treat Rev,1985,12(1):1-47.
  • 10Pohlman B. Ifosfamide in the treatment of non-Hodgkin's lymphoma[J]. Semin Oncol, 1996,23(3 Suppl 6): 27-32.

共引文献25

同被引文献21

  • 1林菁,张军一,李鸣芳,罗荣城.ICE方案治疗复发性难治性非霍奇金淋巴瘤20例[J].实用医学杂志,2005,21(2):169-170. 被引量:6
  • 2谭俊峰,钱申贤,俞巧平,施鹏飞,高大泉,刘利蓉,陈况.含异环磷酰胺方案治疗非霍奇金淋巴瘤55例临床观察[J].实用肿瘤杂志,2005,20(5):426-428. 被引量:2
  • 3杨训,王国惠,叶真,秦桂芳,魏芳.执业医师对药品说明书的理解状况分析[J].中国药房,2006,17(6):473-475. 被引量:9
  • 4陈强,刘建梅,李岚,袁爱群.头孢他定联合盐酸溴己新注射液治疗小儿支气管肺炎的疗效观察[J].江西医学院学报,2007,47(1):66-67. 被引量:7
  • 5Farcet JP.Marolleau JP.Le Couedic JP.et al.Hepatosplenic T-cell lymphoma:sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta.Blood,1990,75(11):2213-2219.
  • 6Delsol C.Diebold J,Isaacson PG.et al.Pathology of the spleen:report on the workshop of the VI th meeting of the European Association for Haematopatholog,Paris 1996.Histopathology,1998,32(12):172-179.
  • 7Falchook GS.Vega F.Dang NH.et al.Hepatosplenic gamma-delta T-cell lymphoma:clinicopathological features and treatment.Ann Oncol,2009,20(6):1080-1085.
  • 8Tey SK.Marlton PV.Hawley CM.et al.Post-transplant hepatosplenic T-cell lymphoma successfully treated with Hyper CVAD regimen.Am J Hematol,2008,83(4):330-333.
  • 9Belhadj K,Reyes F,Farcet JP,et al.Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome:report on a series of 21 patients.Blood,2003,102(13):4261 -4269.
  • 10Kenau HT,Chong G,Cunningham D,et al.Gemcitabin cispl aria and methylprednisolone for the treatment of patients with peripheral T2 cell lymphoma,theRoyal Marsden Hospital expefience[J].Haematologiea,2007,9(2):271-272.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部